Digital health · Oncology remote monitoring
Zealth
A Singapore and Mumbai company that built CareShare, software for watching cancer patients between hospital visits. It went through Antler and Y Combinator, signed hospitals in India, and since 2024 has run as an advisory practice rather than a product company.
Day three
A caregiver identified only as Mohan left a short account on the company website. His brother, a blood cancer patient, had been using the app for three days.
“It was the 3rd day of using Careshare. My brother was alerted as high risk due to high ever severe vomiting. The hospital got an immediate alert and they informed us to take a Complete Blood Count. Careshare helped in saving my brother’s life.”
That is the product in one paragraph. A patient at home answers questions on a phone, an algorithm scores the answers, and a dashboard at the hospital lights up before the family has to decide on its own whether a symptom is worth another trip.
It is also a testimonial the company selected and published. Nothing in the public record tests it.
2,200 oncologists
Zealth’s framing of the gap is blunt. In India, it says, there are only 2,200 oncologists for 1.38 billion people, patients travel 100 miles and wait hours for a few minutes with a doctor. The company attributes 6X lower patient retention and 4X higher emergency readmissions to that gap. Those ratios come from its own Y Combinator listing. No independent source found for this profile supports them.
The version a doctor gave the founders was simpler. “Covid hit that time, and a doctor told us that patients call in every day to ask about their symptoms, and it was beyond their capacity to provide help,” Monika Mehta told the Venture Insider newsletter in January 2022.
A PhD and an IIT engineer
Mehta grew up in a small city in Haryana and finished a PhD at the NUS School of Medicine. She led clinical research at SingHealth and worked as a senior scientist at Chugai Pharma under the Roche group. The lab never paid off fast enough for her: “I grew frustrated not seeing an immediate impact of what I was working on.”
Dheeraj Mundhra holds a dual degree in mathematics and computer sciences from IIT Kharagpur and had spent six years building AI software, from American Express to the food delivery startup TinyOwl. The two met at an accelerator programme in Singapore in early 2020.
What pushed Mehta at it was illness in her own family. On the 2021 version of the company website she described watching a close relative go through treatment: “The entire two years were just full of confusion. Whether to call up the doctor, looking up for information on the internet, what do these tests mean, what do these symptoms mean, am I getting better or getting worse?!?” Mundhra’s half of the same page gave the answer: “We then came up with an end-to-end solution that provides real-time health monitoring and insights using machine learning for easy management of the disease at home.”
COVID first, cancer second
Cancer was the intention. COVID was the market. “I believe that we pivoted 3-4 times with our first idea, which was predicting response to immunotherapy,” Mehta said. Antler funded the company in 2020, and by that September CareShare was monitoring COVID-19 patients in home isolation: temperature, oxygen saturation, a symptom checklist, medications, and a risk score from what the company then called a patent-pending algorithm.
YourStory reported five named hospital customers that month: PGI, Regency Healthcare, Gujarat Critical Care, Apoorva Hospital and Sanjeevan Hospital, with six more in discussion. Mehta said a pilot found about 80 percent of high-risk patients received early intervention because of constant monitoring. In a later interview she put the COVID cohort at 1500 patients.
The long game never changed. “Our long-term plan is to keep innovating, and help patients suffering from other chronic diseases like cancer,” she said in 2020.
Y Combinator took the company into its Winter 2021 batch. TechCrunch, covering the largest Indian contingent YC had admitted, gave Zealth two sentences: “The startup said five hospitals, that together serve over 100,000 patients annual, today are using its software.” That August, Google for Startups picked Mehta for its Women Founders Academy in Asia, describing the company as “a platform that helps manage cancer through digital remote monitoring and patient engagement.”
What it became
The product company did not keep going. Zealth-AI now presents itself as a boutique advisory practice for hospitals, insurers, pharma and healthtech firms across Asia, listing one employee and naming Amplify Health, Emergent and SingHealth among its engagements. Its own account of the earlier chapter is a reach claim and a lesson: “Our platform CareShare was adopted by 21 hospitals across India and Singapore, served over 20,000 patients, and enabled more than 470 timely clinical interventions.” And then: “The hardest part of healthcare AI is not the model. It is the workflow it integrates into, the payment model that funds it, and the trust it earns from clinicians.”
The Indian company is still filing. Zealthlife Technologies India Private Limited, incorporated in Mumbai on 22 July 2020, reported revenue of about 51.78 lakh rupees for the year ended 31 March 2025, up 55 percent.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| Indian registration | CIN U72900MH2020FTC342404, ROC Mumbai, incorporated 22 July 2020 as a foreign subsidiary of Zealthlife Pte. Ltd. Directors Monika, Savita Rani and Dheeraj Mundhra, appointed on incorporation, all current. Authorised capital 20 lakh rupees, paid up 14.62 lakh. No charges registered. | Public record |
| Revenue on file | 51.78 lakh rupees for FY 2025, up 55 percent. Last AGM 30 September 2025. Zero employees against the EPFO establishment as of 1 April 2024. | Public record |
| Hospital customers, 2020 | Five named by YourStory in September 2020 on the founder’s account, for COVID-19 monitoring. | Independent |
| Deployment scale, 2021 | TechCrunch, March 2021: five hospitals serving over 100,000 patients a year. Attributed to the startup, not checked by the outlet. | Independent |
| Lifetime reach claim | 21 hospitals, over 20,000 patients, more than 470 interventions. No hospital names, dates or outcome definitions given. | Company-stated |
| Early intervention figure | About 80 percent of high-risk patients intervened on early during a COVID-19 pilot. Cohort size, comparator and endpoint unpublished. | Company-stated |
| Peer-reviewed work | A PubMed search for the company and product names on 23 September 2026 returned 19 records, all unrelated melanoma papers. | Not found |
| Trials and regulator | No entry in the trial registries pulled for this profile, and no Indian regulatory approval located. | Not found |
| Intellectual property | A patent-pending risk algorithm was claimed in 2020. CB Insights lists one patent, applied 20 December 2019 and granted 21 March 2023, with no title shown and an application date that precedes the company. | Unconfirmed |
Read plainly: Zealth proved it could get installed. Five named hospitals in its first seven months, a YC batch, a Google program, and a company still filing accounts in Mumbai six years on. What it never produced in public is a study with a denominator. The 470 interventions and the 80 percent are the company’s own arithmetic on its own data.
What to watch
- Whether the advisory business is the destination or a holding pattern. One employee listed, revenue growing off a small base.
- Any retrospective write-up of the CareShare cohort. Twenty thousand monitored cancer patients is a publishable dataset.
- Whether the named hospitals kept the software after the COVID-19 emergency. None has said so publicly.
- A granted patent title, which would confirm or kill the CB Insights match.
In their words
“The entire two years were just full of confusion. Whether to call up the doctor, looking up for information on the internet, what do these tests mean, what do these symptoms mean, am I getting better or getting worse?!?”
Monika Mehta, co-founder and CEO, company website, 2021 · Company
“Covid hit that time, and a doctor told us that patients call in every day to ask about their symptoms, and it was beyond their capacity to provide help.”
Monika Mehta, Venture Insider, January 2022 · Interview
“I believe that we pivoted 3-4 times with our first idea, which was predicting response to immunotherapy.”
Monika Mehta, Venture Insider, January 2022 · Interview
“So basically Zealth is software that provides remote monitoring through an app that keeps you connected with your hospital, whichever part of the world it is and that data goes to the hospital in real-time.”
Monika Mehta to MediCircle · Interview
“CareShare has made patient follow up simple and effective. It has significantly increased patient engagement.”
Dr. Aarti Sinha, testimonial on the company website, 2021 · Company
“The hardest part of healthcare AI is not the model. It is the workflow it integrates into, the payment model that funds it, and the trust it earns from clinicians.”
Zealth-AI company page, 2026 · Company
Related companies
Sources
- Public recordZealthlife Technologies India Private Limited, CIN U72900MH2020FTC342404, MCA registry data
- Public recordPubMed search for Zealth and CareShare, 19 records, none related
- Public recordForm D, Zealth, Inc., CIK 0001892475, a different company in San Mateo
- IndependentZealth.ai: a one-stop platform for real-time remote monitoring of COVID-19 patients
- IndependentY Combinator’s new batch features its largest group of Indian startups
- Interview#42 Monika Mehta: Against All Odds
- InterviewIt’s all about keeping the patient connected to their doctor
- IndependentMore support for women founders in Asia
- IndependentZealth profile, funding and patent record
- IndependentZealth deal history and investor list
- IndependentNotable raises $100M at a $600M valuation
- IndependentRemote jobs at Zealth, Inc. DBA Notable Health
- CompanyZealth-AI website, founder statements and testimonials
- CompanyZealth-AI company page, advisory positioning and reach figures
- CompanyZealth company listing and problem framing
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
